Artículo
Abstract:
Vernakalant has proved to be more rapid in converting recent onset AF to sinus rhythm compared to placebo, amiodarone, propafenone and flecainide. In many centers around the world the electrical cardioversion is the first line of treatment of acute atrial fibrillation. Recently a group published that vernakalant had a 90% conversion rate in patients with recent onset atrial fibrillation without structural heart disease versus 100% conversion rate in the electrical cardioversion group. In this study there was no statistical differences between both groups (p = NS). Vernakalant has been approved in Europe and South America, but it has not been approved in the United States and Canada. FDA wants a megatrial to show the real benefits of vernakalant compared to other drugs including electrical cardioversion. The trial ACT V has been canceled because one patient who received vernakalant died and this is the reason why FDA has not approved vernakalant yet. We do not know the real condition of the patient and if it was corrected to conclude that the severe adverse event had a direct relationship with the drug. I can conclude that it is time to design a megatrial to show if vernakalant is better or not for conversion of recent onset atrial fibrillation compared with other antiarrhythmic drugs and electrical cardioversion because all the topics about this drug have been published but in brief reports. We need a big trial to know the real safety of this drug. © 2013 Elsevier Ireland Ltd.
Registro:
| Documento: | Artículo |
| Título: | Is vernakalant better or not compared with other treatments for conversion acute atrial fibrillation? |
| Autor: | Conde, D. |
| Filiación: | Instituto Cardiovascular de Buenos Aires, Blanco Encalada 1543, 1428 Buenos Aires, Argentina |
| Palabras clave: | Amiodarone; Atrial fibrillation; Electrical cardioversion; Flecainide; Propafenone; Vernakalant; amiodarone; flecainide; placebo; propafenone; vernakalant; acute disease; cardioversion; drug approval; drug blood level; drug distribution; drug efficacy; drug fatality; drug half life; drug mechanism; drug safety; Europe; food and drug administration; heart atrium fibrillation; hemodynamics; human; loading drug dose; priority journal; review; risk reduction; single drug dose; sinus rhythm; South America; study design; treatment outcome; Amiodarone; Atrial fibrillation; Electrical cardioversion; Flecainide; Propafenone; Vernakalant; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Resynchronization Therapy; Humans; Pyrrolidines; Treatment Outcome |
| Año: | 2013 |
| Volumen: | 169 |
| Número: | 2 |
| Página de inicio: | 95 |
| Página de fin: | 96 |
| DOI: | http://dx.doi.org/10.1016/j.ijcard.2013.08.139 |
| Título revista: | International Journal of Cardiology |
| Título revista abreviado: | Int. J. Cardiol. |
| ISSN: | 01675273 |
| CODEN: | IJCDD |
| CAS: | amiodarone, 1951-25-3, 19774-82-4, 62067-87-2; flecainide, 54143-55-4; propafenone, 34183-22-7, 54063-53-5; vernakalant, 748810-28-8, 794466-70-9 |
| Registro: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_01675273_v169_n2_p95_Conde |
Referencias:
- Go, A., Hylek, E., Phillips, K., Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study (2001) JAMA, 285, pp. 2370-2375
- Li, H., Easley, A., Barrington, W., Windle, J., Evaluation and management of atrial fibrillation in the emergency department (1998) Emerg Med Clin North Am, 16, pp. 389-403
- Boriani, G., Capucci, A., Lenzi, T., Sanguinetti, M., Magnani, B., Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration (1995) Chest, 108, pp. 355-358
- Khan, I.A., Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation (2001) J Am Coll Cardiol, 37, pp. 542-547
- Roy, D., Rowe, B.H., Stiell, I.G., A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation (2004) J Am Coll Cardiol, 44, pp. 2355-2361
- Roy, D., Pratt, C., Torp-Pedersen, C., Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial (2008) Circulation, 117 (12), pp. 1518-1525
- Kowey, P., Dorian, P., Mitchell, L., Vernakalant hydrochloride for rapid conversion of atrial fibrillation after cardiac surgery: A randomized, double blind, placebo-controlled trial (2009) Circ Arrhythm Electrophysiol, 2, pp. 652-659
- Camm, A.J., Capucci, A., Hohnloser, S.H., A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation (2011) J Am Coll Cardiol, 57, pp. 313-321
- Conde, D., Costabel, J.P., Aragon, M., Propafenone versus vernakalant for conversion of recent-onset atrial fibrillation (2013) Cardiovasc Ther, , 10.1111/1755-5922.12036
- Conde, D., Costabel, J.P., Caro, M., Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation (2013) Int J Cardiol, 57, pp. 2423-2425
- Conde, D., Costabel, J.P., Aragon, M., Lambardi, F., Trivi, M., Vernakalant: Perception of state of health in patients with a recent-onset atrial fibrillation (2013) Cardiol J, , 10.5603/CJ.a2013.0113
- Conde, D., Lalor, N., Rodriguez, L., Elissamburu, P., Trivi, M., Vernakalant versus electrical cardioversion in recent-onset atrial fibrillation (2013) Int J Cardiol, 168, pp. 4431-4432
Citas:
---------- APA ----------
(2013) . Is vernakalant better or not compared with other treatments for conversion acute atrial fibrillation?. International Journal of Cardiology, 169(2), 95-96.http://dx.doi.org/10.1016/j.ijcard.2013.08.139
---------- CHICAGO ----------
Conde, D. "Is vernakalant better or not compared with other treatments for conversion acute atrial fibrillation?" . International Journal of Cardiology 169, no. 2 (2013) : 95-96.http://dx.doi.org/10.1016/j.ijcard.2013.08.139
---------- MLA ----------
Conde, D. "Is vernakalant better or not compared with other treatments for conversion acute atrial fibrillation?" . International Journal of Cardiology, vol. 169, no. 2, 2013, pp. 95-96.http://dx.doi.org/10.1016/j.ijcard.2013.08.139
---------- VANCOUVER ----------
Conde, D. Is vernakalant better or not compared with other treatments for conversion acute atrial fibrillation?. Int. J. Cardiol. 2013;169(2):95-96.http://dx.doi.org/10.1016/j.ijcard.2013.08.139
